Make the best use of Scientific Research and information from our 700+ peer reviewed, 黑料网 Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
Editorial 黑料网
No Dual Antiplatelet Therapy in Atrial Fibrillation
| Antonio L Aguilar-Shea* | |
| Centro de Salud Puerta de Madrid, Spain | |
| *Corresponding Author : |
Antonio L Aguilar-Shea |
| Received date: April 15, 2016; Accepted date: April 15, 2016; Published date: April 19, 2016 | |
| Citation: Aguilar-Shea AL (2016) Double High Risk Atrial Fibrillation Patient´s. Arrhythm 黑料网 1:e103. doi:10.4172/atoa.1000e103 | |
| Copyright: © Aguilar-Shea AL. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution, and reproduction in any medium, provided the original author and source are credited. | |
Visit for more related articles at
| Editorial |
| Managing atrial fibrillation is common in daily practice and an important part of this management is deciding over the embolism prevention strategy. Oral anticoagulants (warfarin, acenocumarol, apixaban, rivaroxaban or dabigatran) and antiplatelets (acetylsalicylic acid or clopidogrel) are the two groups of drugs used to prevent embolism events. To choose wisely CHA2DS2-VASc embolism risk scale aids in making this decision. But, is dual antiplatelet therapy, acetylsalicylic acid plus clopidogrel, a correct option in embolism prevention in atrial fibrillation? |
| A primary source search was done in Pubmed (Medline) using as key words “dual antiplatelet therapy and atrial fibrillation” and the most relevant articles were chosen [1-4]. Secondary sources guidelines were also reviewed, but only two major guidelines discussed this matter, European Society of Cardiology [5] and Uptodate [6]. The conclusion was that double anticoagulation was not an appropriate treatment for embolism prevention in atrial fibrillation. The risk of bleeding of dual antiplatelet therapy was similar to the anticoagulation therapy but the embolism prevention was much lower. |
| References |
|
Share This Article
Relevant Topics
Recommended Journals
Article Tools
Article Usage
- Total views: 9443
- [From(publication date):
July-2016 - Nov 22, 2024] - Breakdown by view type
- HTML page views : 8797
- PDF downloads : 646
